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Abstract
A molecular hallmark of cancer is the presence of genetic alterations in the tumoral DNA. Understanding how
these alterations translate into the malignant phenotype is critical for the adequate treatment of oncologic dis-
eases. Several cancer genome sequencing reports have uncovered the number and identity of proteins and path-
ways frequently altered in cancer. In this article we discuss how integration of these genomic data with other
biological and proteomic studies may help in designing anticancer therapies “a la carte”. An important conclusion
is that next generation treatment of neoplasias must be based on rational drug combinations that target various
pathways and cellular entities that sustain the survival of cancer cells.
Review
A critical step towards defining a correct personalized
anticancer therapy is the identification of the genes and
pathways altered in the tumour of the patient, and the
elucidation of their particular oncogenic role. The suc-
cess of molecular studies in identifying potential mole-
cular targets for therapeutic intervention is exemplified
by the developments in the treatment of chronic myelo-
genous leukaemia (CML) [1]. This disease is character-
ized by the presence of the Philadelphia chromosome,
created by a translocation which provokes constitutive
activation of the tyrosine kinase Abl. The identification
of this molecular alteration fostered the development of
drugs such as Imatinib Mesylate that inhibit Abl kinase
activity and successfully control the disease [2]. How-
ever, in most solid tumours multiple genetic lesions are
expected to be required for tumour progression [3]. In
fact, the clinical experience in the treatment of oncolo-
gic diseases indicates that combinations of drugs that
act on different cellular targets demonstrate superiority
over single agent-based treatments [4]. Yet, these com-
bined treatments are mostly based on empirical trials
and lack, in many instances, a biological rationale [5,6].
Given the positive experience that molecular knowledge
has offered for the treatment of CML, efforts have been
made to define the molecular alterations present in the
DNA of distinct types of tumours. Here we will com-
ment how novel high throughput techniques may help
in finding more adequate and less toxic personalized
anticancer therapies.
Somatic alterations in the cancer genome
In designing proper anticancer therapies the clinical and
the preclinical researchers face several important ques-
tions: How many genetic alterations exist in a tumour?
How many of them are responsible of promoting tumour
growth? How many should be targeted to eradicate the
tumour? The availability of technologies that allow large
scale sequencing and genomics analyses of several
tumours, together with strong bioinformatics tools and
functional studies are contributing to answering these
questions. Recent studies on the molecular profiling of
breast and colon [7,8], lung [9-11], glioblastoma [12,13]
and pancreatic [14] cancers have described alterations in
multiple genes and pathways important for the control of
cell number in these tumours. Although this is an already
known concept, the value of these studies is that by
sequencing of the whole transcriptome of individual
tumours the researchers have uncovered the number of
mutated genes as well as their identity. In the analysis of
the genomes of breast and colorectal cancers [7], between
60 and 80 mutations that alter the amino acid sequence of
proteins (non-silent mutations) were detected in a single
tumour (Table 1). Noteworthy, although some of the
genes were overlapping, most of them were not coinci-
dent, not only when comparing breast and colon tumours,
but also when comparing tumours of the same type but
from distinct patients. It should however be mentioned
that these transcriptomic sequencing studies, while offer-
ing important molecular information on individual
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lyses, as they may, for example, miss the overexpression of
non-mutated HER2 that is present in one out of four
patients with breast cancer, and that represents a relevant
clinical target [15]. Another more recent study identified a
larger number (292 mutations in coding regions, of which
187 were non-synonymous) of mutated genes in a cell line
of colorectal cancer [16]. It is possible that these differ-
ences may stem from the fact that some works reported
results from patients, while others used cell lines which
may accumulate lesions along their in vitro establishment.
On the other side, sequencing of acute myeloid leukaemia
(AML) samples have identified 10 mutations in protein-
coding mRNAs [17,18]. Additional massive sequencing
efforts, such as those carried out by the International Can-
cer Genome Consortium, will help in establishing a more
accurate measurement of the average mutated genes/
tumour.
By using bioinformatics analyses those authors indi-
cated that most of the mutations in an individual breast
or colon tumour were silent in terms of favouring
tumour progression [7]. These analyses indicated that
not more than 15 genes, that they term CAN genes
(from “cancer” genes), are responsible for supporting
tumour viability in each tumour. Some of the mutations
identified affected genes that participate in the PI3K or
NFB routes, two pathways linked to cell survival/prolif-
eration, and that are potential therapeutic targets (Table
2). An important question that must be addressed is
how many of these CAN genes must be targeted
for efficient therapy of a tumour. On the basis of age-
incidence data, some authors proposed that genetic
alterations in 5-7 CAN genes may be required for solid
tumour generation [19], and it is therefore expected that
targeting of these genes or some of their downstream
actor proteins may be therapeutically effective. We will
Table 1 Somatic mutations in cancer exomes and pathways affected
Tumour type
(sample size)
Genes
analyzed
Average number of
mutated genes/
patient
Major pathways deregulated References
Breast (n = 11) 18,191 62 RTKs, PI3K, NFB, [7]
Colorectal cancer
(n = 11)
18,191 88 RTKs, PI3K, Cell adhesion, Cytoskeleton, Extracellular matrix [7]
Colorectal cancer
(n =1 )
Genome 292 Transcription (SPDEF), Metalloproteases (MMP28), PI3K, BRAF [16]
Glioblastoma (n =
22)
20,661 47 RTKs, PI3K, Cell cycle, DNA damage (p53), Neuronal-type pathways
(ionic channels), IDH1
[13]
Pancreas (n = 24) 20,661 48 KRAS signalling, DNA damage control, Cell cycle, TGFb pathway, Wnt/
Notch signalling, Cell adhesion and integrin signalling, MAPK signalling,
Apoptosis
[14]
Glioblastoma (n =
206)
601 selected
genes
NA RTKs, NF1, DNA damage, PI3K, Cell cycle, methylation, mismatch repair [12]
Lung cancer (n =
188)
623 genes
implicated in
cancer
NA RTKs, DNA damage control, RAS (K and N), NF1, LRP1B (lipid
metabolism), MAPK signalling, Wnt signalling, STK11 (Ser/Thr kinase)
[10]
Lung cancer (n =
371)
NA NA Cell cycle, PI3K, RTKs, Tyrosine phosphatases, cAMP, Angiogenesis,
NKX2-1 (pneumocyte differentiation)
[9]
Lung cancer (n =
1)
Genome 134 Cell cycle (Rb), DNA damage (p53), DNA helicase CHD7 [11]
Mesothelioma (n =
4)
15,000 6 DNA damage, Extracellular matrix, Mitochondrial reductase activity,
proteasome, Apoptosis
[54]
Diverse cancers (n
= 210)
518 kinases NA RTKs, JNK, MAPK,, BRAF, DNA damage control [20]
Renal cancer, clear
cell (n = 101)
3544 NA Histone modifications (SETD2, JARID1C, UTX), VHL, NF2, HIF1A, PMS1
(DNA mismatch repair), WRN and NBN (DNA double strand repair)
[55]
Diverse cancers (n
= 3131)
NA NA Kinases, cell cycle, NFB, Myc, Apoptosis, Cell adhesion, DNA
methylation, microtubule organization, transcription
[22]
Acute Myeloid
leukaemia ((n =1 )
Genome 10 NRAS, NPM1, IDH1, CDC42, IMPG2, ANKRD46, LTA4H, FREM2, CEP170 [17,18]
Ovarian granulosa
cell tumours (n =
4)
Genome NA FOXL2 [56]
RTKs: receptor tyrosine kinases. NA: not available
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port the use of a restricted number of targettable pro-
teins that fall within that latter number.
Additional studies carried out in glioblastoma multi-
forme (GBM) [12,13] and pancreatic cancer [14], in
addition to describing the somatic alterations in the
DNA, advanced to more precisely defining the molecu-
lar pathways altered in these pathologies. Interestingly,
in these tumours the number of mutated genes was
lower (around 40 mutations/tumour) than in breast or
colorectal cancer. By using similar and complementary
techniques to search for point mutations, as well as
gains and losses of genetic material, the two different
reports analyzing the genomes of patients with GBM
satisfyingly came to common conclusions [12,13]. These
reports observed frequent alterations in three major sig-
nalling pathways that control cell proliferation: the
receptor tyrosine kinase-PI3K route, the p53, and the
retinoblastoma (RB) tumour suppressor pathways. Inter-
estingly, some of these pathways were also found to par-
ticipate in pancreatic as well as colon and breast cancer
tumours, indicating overlapping of signalling pathways
that may be critical in the genesis/progression of solid
tumours. Interestingly also was the fact that mutations
in the genome of GBM patients accumulated in patients
treated with the alkylating agent temozolomide, a che-
motherapeutic used in this pathology which is also
highly mutagenic. Moreover, another study in which the
genes coding for kinases of patients with several types of
cancer were analyzed also showed that the highest pre-
valence of mutations in the kinases corresponded to
GBM patients treated with temozolomide [20]. This
indicates that resistance mechanisms may develop in
Table 2 Drugs in clinical development against pathways
identified in genomic/proteomic studies
Receptor Tyrosine Kinases
Pan-ErbB receptors
CI-1033 Pfizer phase II[57,58]
BIBW-2992 Boehringer Ingelheim phase II[57,59]
Neratinib Wyeth-Ayerst phase III[60,61]
MET
MK-2461 Merck phase I/II[62]
XL184 Exelixis phase II/III[62]
MetMAb Genentech phase I[63]
FGFR
MK-2461 Merck phase I/II[62]
Brivanib BMS phase II[64]
K-RAS-RAF
PLX4032 Plexxikon Inc/Roche phase I[65]
PI3K-AKT Inhibitors-mTOR
Dual PI3K-mTOR
BEZ235 Novartis phase I/II[30,66,67]
XL765 Exelixis phase I[68]
SF1126 Semafore phase I/II[68,69]
BGT226 Novartis phase II[68]
PI3K Inhibitors
XL147 Exelixis phase I[68]
BKM120 Novartis phase I[68]
GDC0941 Genentech phase I[70,71]
AKT inhibitors
Perifosine Keryx phsae I/II[72-74]
GSK690693 GSK phase I[75-77]
MK2206 Merck phase I[68]
mTOR
OSI027 OSI Pharmaceuticals phase I[68]
AZD8055 AstraZeneca phase I/II[68]
MAPK inhibitors
MEK Inhibitors
CI-1040 Pfizer phase I/II[78,79]
AZD6244 AstraZeneca phase I/II[80,81]
XL518 Genentech phase I[71]
Cell Cycle
Flavopiridol Sanofi-aventis phase II/III[82]
SNS-032 BMS phase I/II[31]
R-547 Roche Phase I/II[83,84]
Seleciclib Cyclacel Pharmaceuticals Phase I/II[85]
Histone Deacetylase inhibitors
Vorinostat
(SAHA)
Merck Phase I/II[86]
Romidepsin Gloucester Pharmaceuticals Phase I/II[87,88]
MGCD0103 MethylGene, Inc phase I/II[89]
LBH589 Novartis phase I/II[90,91]
Table 2 Drugs in clinical development against pathways
identified in genomic/proteomic studies (Continued)
Demethylating agents
Azacitidine Celgene approved[92,93]
Decitabine Eisai Pharmaceuticals approved[94]
DNA repair
PARP
Olaparib KuDOS Pharmaceuticals/
AstraZeneca
phase II[95]
AG-014699 Pfizer phase II[96]
ATM
KU-55933 KuDOS Pharmaceuticals preclinical[97]
Matrix Metalloproteinases
Neovastat Æterna Laboratories phase III[98,99]
Prinomastat Pfizer phase III
[98,100,101]
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favour the development of clones of cells resistant to
the action of classical treatments. The sequencing efforts
carried out in GBM also identified isocitrate dehydro-
genase 1 (IDH1) as a protein that could act in the
pathogenesis of this disease [13,21]. Interestingly, IDH1
was also found to be mutated in the genome of AML
patients [18].
In lung cancer, using single nucleotide polymorphism
( S N P )a r r a y s ,W e i re ta l .[ 9 ]a n a l y z e dt h ep r e s e n c eo f
copy-number alterations of chromosomal regions in a
large proportion (n = 371) of lung tumours, and found
frequent gains or losses of chromosomal regions. Some
genomic alterations, such as copy number gain of chro-
mosome 5p occurred in a high number of patients
(60%). These alterations affected genes known to be fre-
quently involved in lung cancer, such as EGFR/HER1,
CCNE1,o rKRAS. In addition, the paper describes a
novel player in lung cancer pathophysiology, the NKX2-
1 gene product, a transcription factor implicated in the
formation of lung pneumocytes. Knocking down the
expression of this protein in NCI-H1925 lung cancer
cells decreased their ability to grow in an anchorage-
dependent manner, indicating that this protein may
represent a novel lung cancer promoting oncogene, and
an interesting novel therapeutic target. Another report
analyzed somatic mutations of 623 genes in 188 lung
cancer samples [10]. These genes were selected for their
already known implication in oncogenesis. KRAS or
EGFR were mutated in a substantial proportion of
patients; but, in addition, several other genes not for-
merly associated to lung cancer were identified, and
included tumour suppressors (NF1, RB, ATM,a n d
APC), as well as tyrosine kinase genes (ERBB4,e p h r i n
receptor genes, KDR, FGFR4,a n dNTRK). Of note, 132
of the 188 tumours had at least one mutation in genes
that participate in MAPK signalling. Also, mutations in
multiple genes of the Wnt pathway were observed in 29
of the 188 samples. Frequent mutations were also
detected in DNA damage response genes, including
TP53,a n dATM. This clustering of mutations in certain
pathways which play a role in oncogenesis points to the
possibility of interfering with them for the treatment of
lung tumours. Moreover, from a more ample perspective
the molecular studies mentioned above open outstand-
ing possibilities in terms of better focusing on certain
targeted therapies for these tumours, based on drugs
that target components of the identified signalling path-
ways. Another report confirmed the relevance of p53
and Rb in lung cancer [11]. Here the researchers
sequenced the whole genome of a lung cancer cell line
and found 22,910 somatic mutations, of which 134 were
included into coding exons, 94 of them causing changes
in the primary sequence of the coded proteins.
An ample study of somatic copy number alterations
performed on 3131 tumour samples, and also using high
resolution SNP arrays identified a median of 12 gains
and loses in each patient tumour [22]. Frequent altera-
tions in the control of cell cycle progression, apoptosis,
DNA damage control, or kinase activity were reported.
The contribution of functional genomics to cancer
therapy
A strategy that has been recently developed to massively
identify potentially useful therapeutic targets is based on
functional genomics studies using RNA-interference
(RNAi) screenings. In one such functional screen based
on the knockdown of 2,924 genes selected for their
potential implication in tumour generation/progression,
Schlabach et al. identified between 80-150 gene products
important for tumour survival/proliferation [23]. Of
them, 19 genes were shared by the three distinct
tumoral cell lines analyzed (two from colon cancer, and
one from breast cancer). Interestingly, the list of the
identified proteins showed significant overlap between
distinct tumoral cell lines, but were different from those
identified to be essential for the survival of normal
breast epithelial cells [23]. This indicates the existence
of qualitative differences between normal and malignant
cells with respect to proteins that support their respec-
tive viabilities. This is highly relevant from the therapeu-
tic point of view, as it indicates that the targeting of
proteins that specifically support survival of cancer cells
is realistic, and may spare normal cells, therefore repre-
senting an efficient and likely safe therapeutic strategy.
In addition, these authors also found a certain degree of
overlapping between proteins that support viability in
tumours from the same tissue origin. However, they
also found proteins whose function was required to sus-
tain viability of one tumour cell, but did not play a criti-
cal survival role in others. Thus, knock down of the
protein phosphatase PP1 seriously affected survival of
HCC1954 colon cancer cell line, but did not substan-
tially affect DLD-1 colon cancer cells. These results sup-
port the concept of the distinct susceptibility of different
tumours, and stress the importance of adequately select-
ing protein targets to achieve therapeutic success. Ana-
logous functional genomic studies in haematological
malignancies led to the identification of the IRF4 and
genes regulated by this protein as potential therapeutic
targets in multiple myeloma [24], and the demonstration
that tyrosine kinases play an important role in sustain-
ing AML vitality [25]. This last work is particularly
interesting as the authors used fresh samples from
patients to identify, by also using RNAi techniques,
potentially relevant drug targets. More ample RNAi
screening techniques, based on the knockdown of up to
17,000 different genes [26], have allowed an almost
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tumour survival, and have identified pathways and pro-
teins that participate in tumour proliferation/survival
[27].
In addition to finding potentially useful drug targets,
these RNAi-based functional genomic screens have also
been used to uncover mechanisms of drug resistance.
Bernards and colleagues explored proteins involved in
trastuzumab resistance in breast cancer and identified
PTEN as one of the principal proteins whose lack of
function was linked to trastuzumab resistance [28], in
agreement to previous reports [29]. Moreover, preclini-
cal data indicated that combination of agents that target
HER2 and the PI3K route reverts resistance to trastuzu-
mab [30].
In spite of the value of these studies, one of the poten-
tial pitfalls is the identification of relevant targets in
vitro whose in vivo manipulation could be highly toxic.
It is therefore mandatory to proceed into in vivo testing
the manipulation of those targets (Figure 1).
Biological findings support the use of combined targeted
therapies
An important aspect of the functional genomics assays
is the finding of individual proteins whose targeting is
deleterious for the tumoral cell, opening the door to the
development of drugs that by interfering with their
action may be therapeutically relevant as single agents.
However, as mentioned above, the clinical experience
suggests that efficient cancer treatment usually relies on
the combination of agents that target distinct oncogenic
networks. The fact that combination of agents may be
more efficient than single agent treatment may be due
to the heterogeneity of tumours, in some cases pro-
moted by some anticancer treatments that either act as
mutagens, as mentioned above in temozolomide-treated
patients, or by the mutational heterogeneity within a
single tumour. This heterogeneity has been recently pro-
posed as a limit for the value of high throughput
sequencing efforts in individual tumours [31]. The
cross-talk between intracellular signalling pathways
mainly activated by RTKs represents another reason to
explain the efficacy of combination strategies. It has
been reported that inhibition of certain pathways, such
as the mTOR route may lead to increased MAPK activ-
ity [32]. Therefore, ablation of signals through both
routes is required for efficient antitumoral action. More-
over, combined inhibition of PI3K and MAPK routes
has shown superior antitumoral effect compared to indi-
vidual targeting of either pathway [33].
Elegant biological studies supporting that adequate
targeted drug combinations based on genomic profiling
may be effective in cancer treatment has been offered by
reports from the Massagué group [34,35]. These
researchers used genomic and imaging techniques to
analyze a particularly relevant property of tumoral cells,
i.e. metastatic dissemination. Their strategy was based
on the injection of a breast cancer cell line into the
bloodstream of mice, and the selection of tumoral
clones that homed to several organs. In their studies,
genomic profiling identified signatures of genes that
were particular of the cells that metastatized to a certain
tissue. The researchers then selected some of these
genes for further biological analyses, and suspected that
f o u ro ft h e m ,E p i r e g u l i n ,C O X 2 ,M M P 1a n dM M P 2 ,
represented therapeutic candidates in the case of lung
metastases. In fact, experiments of gene knockdown
confirmed the importance of these genes in breast can-
cer tumour growth in nude mice. Interestingly, single
knockdown of only one of the coding mRNAs had little
effect on the growth of these tumours as compared to
double knockdowns. But the most impacting results
were obtained by quadruple knockdowns. Reduction of
the expression of the four mRNAs coding for the
respective proteins fully abrogated tumour growth.
These genomic-functional studies were complemented
with targeted therapies aimed at neutralizing the activity
of the four selected protein targets. Again, single agent
treatment was less effective than combinations in pre-
venting extravasation and lung colonization by the
tumoral cells. Also, combination of three targeted
agents, expected to neutralize the function of all four
proteins, was more effective than dual combinations,
and the triple combinations almost fully prevented lung
invasion by the tumoral breast cancer cell population.
Another recent analogous study identified a set of genes
that mediate breast cancer metastasis to the brain [36].
Interestingly, some of them (COX2 and HB-EGF) share
molecular identity or properties with those formerly
described to participate in metastatic spreading to the
lung. However, other proteins such as the sialystransfer-
ase ST6GALNAC5 was specific for cells that metasta-
tized to the brain, and could be involved in facilitating
cell passage through the blood brain barrier. The find-
ings of Massagué and colleagues come in support of the
well established clinical concept that drug combinations
are superior in efficacy to single agents to treat solid
tumours. The added value of their work is the use of
molecular and biological tools to define and verify ade-
quate targets for therapeutic intervention.
Combined targeted therapies guided by proteomic
studies
Probably the genomic portraits are insufficient in guid-
ing the selection of antitumoral therapies. Indeed, stu-
dies on receptor tyrosine kinase (RTK) targeting in
cancer have offered insights into the convenience of
complementing the genomic data with proteomic
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mel et al. [37] analyzed the phosphotyrosine content
(indicative of activation) of 42 different RTKs in GBM.
This disease may present alterations of the EGFR that
result in its constitutive activation. However, response
r a t e st oa g e n t st h a tt a r g e te x c l u s i v e l yt h eE G F Ra r e
poor. Stommel et al. found consistent activation of three
or more RTKs in 19 out of 20 GBM cell lines. These
RTKs included the EGFR, ErbB3/HER3, platelet-derived
growth factor receptor a (PDGFRa), and MET. These
Oncogenic Alterations
“Omics” analyses
Targeted Drug Combinations
Mutation and copy 
number analyses
Identification of molecular 
alterations
Human Cancer 
Proteomic studies
In vitro and in vivo validation
(efficacy and safety)
Clinical Studies
Transcriptomic studies
Figure 1 Stepwise selection of antitumoral therapies based on individual oncogenic alterations. Analyses of oncogenic alterations in
individual tumour samples using “omics” techniques should allow the identification of candidate targets for therapeutic intervention.
Experimental preclinical validation of these targets is critical in order to proceed to the clinical testing of drugs that act on the selected targets.
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activated receptors using several in vitro models. Inhibi-
tion of the activity of individual receptors had a mar-
ginal effect on the growth properties of the GBM cell
lines. However, combination of drugs that targeted two
receptors was superior to single agent treatments.
Furthermore, triple combinations were more efficient
than double combinations, and practically abolished
tumour growth in soft agar colony forming assays. The
authors conclude that coactivation of multiple RTKs
may sustain cell proliferation in GBM, and that ade-
quate treatment of this pathology must include a careful
evaluation of the RTKs activated.
In line with those findings, two additional reports
showed the importance of targeting multiple RTKs in
breast [38] and lung cancers [39]. Both studies
attempted to identify the mechanisms of resistance to
therapies that target HER (Human EGFR-like Receptors)
receptors. In the breast cancer study, resistance to gefiti-
nib or erlotinib, agents that act on the EGFR/HER1, was
accompanied by increased tyrosine phosphorylation of
ErbB3/HER3 [38]. Similarly, gefitinib resistance in lung
cancer was also found to be accompanied by ErbB3/
HER3 signalling [39]. This up-regulation of ErbB3/HER3
signalling was due to amplification of MET. Concomi-
tant treatment with gefitinib and the MET inhibitor
PHA665752 provoked a decrease in cell survival not
obtained by single drug treatments. The fact that multi-
kinase inhibitors have reached the oncology clinic adds
value to these experimental results and paves the way
for the development of multikinase targeting strategies
guided by proteomic analyses of the activation state of
the kinome.
Limitations of targeted therapies based on genomic
profiling
While the above mentioned studies offer unquestionable
useful information about relevant targets for therapeutic
intervention in cancer, several factors that can limit the
efficacy of targeted therapies must be considered. One is
the presence of molecular heterogeneity within a parti-
cular tumour [40]. The well known genetic instability of
tumour cells may be responsible for the generation of
different subclones of tumoral cells that could be repre-
sented at different amounts in the tumoral tissue (Figure
2). Those present in higher amounts are expected to be
responsible for providing the genomic information,
diluting the genomic landscapes of other tumoral cells
present at lower amounts. The latter therefore escape
detection by those genomic/proteomic analyses and
result in tumour relapse, since targeted therapies are
expected to focus on alterations present in the mostly
abundant cells. Exemplifying this concept is the fact that
chronic exposure to gefitinib, an agent that targets the
EGFR, results in emergence of resistant lung cancer
cells bearing a mutation in the EGFR that renders these
tumoral cells insensitive to the drug [41]. Presumably,
cancer initiating/stem cells represent another source of
failure to targeted treatments, as they are expected to
represent a minority of the cellular constituents of the
tumour. Strategies to identify drugs that target these
tumour initiating cells are being developed and may
represent useful additions to targeted therapies [42].
Another factor that limits the efficacy of targeted
agents is the presence of parallel activation of down-
stream pathways. A well characterized example is the
preclinical identification of the lack of antitumor activity
of agents against RTKs when mutations at the K-RAS
and PI3K genes were present [43,44]. Translation of
these studies to the clinic confirmed lack of activity of
anti-EGFR antibodies like cetuximab or panitumumab
in colon cancer tumours with K-RAS mutations [45,46].
These studies have been of much importance in selec-
tion of anti-EGFR therapies in colorectal cancer, as
patients whose tumours express mutated forms of
K-RAS are now excluded from treatments based on
anti-EGFR drugs. In addition, among colorectal tumours
carrying wild-type KRAS, other additional mutations in
genes participating in EGFR signalling may cause resis-
tance to anti-EGFR therapies. Thus, mutation of BRAF
or PIK3CA or loss of PTEN expression may result in
resistance to EGFR-targeted monoclonal antibody treat-
ment [47,48].
Another important tumour component that is gaining
importance as a targettable cell type is the stromal com-
partment. In multiple myeloma, a disease characterized
by the accumulation of tumoral plasma cells, the inter-
action of these cells with the stroma is expected to be
critical for sustaining survival of the myelomatous cells,
and to provide drug resistance [49]. Moreover, treat-
ments that target both the myeloma cell and the bone
marrow microenvironment, such as the proteasome
inhibitor bortezomib, or the immunomodulatory agents
derived from thalidomide, have shown anti-myeloma
activity and have reached the myeloma clinic [50]. Inter-
estingly, genetic studies have demonstrated the presence
of genetic alterations in the bone marrow mesenchymal
cells of patients with multiple myeloma, supporting the
concept that the stroma in the vicinity of the tumour
may be cancerized [51]. In other neoplastic pathologies
such as breast cancer, mesenchymal stem cells have
been shown to promote metastatic dissemination of the
tumoral cells [52]. Moreover, recent studies perfomed in
myelodisplastic syndromes support the concept that
initial alterations in the stromal compartment may
favour the generation of secondary leukemias in a
mouse model, further supporting a potential role of the
stroma in the pathophysiology of at least certain
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must also take into consideration these variables in
order to achieve long lasting remissions.
Concluding remarks
The power of high scale “omics” analyses coupled with
the ample portfolio of targeted drugs under clinical
development and already approved offers hope for a
more effective and individualized anticancer therapy. It
is rewarding to observe that sophisticated genomic, pro-
teomic and biological studies reinforce the already
known clinical strategy of using drug combinations to
treat cancer patients (Figure 1). The molecular and bio-
logical data herewith commented also offers clues as to
how many targets, pathways or functions should be
attacked. The preclinical evidence that targeting from
one to four proteins may impede proliferation, survival
or invasion properties of cancer cells indicates that
these cells depend on a limited number of proteins to
carry out these biological functions. That the studies
mentioned above have correctly targeted some of these
molecules is beyond doubt. However, it is possible that
targeting other proteins could have a similar impact. In
fact, few overlap exists between the molecules targeted
in each of these individual papers, especially those that
used functional genomics to identify potential targets.
This can be interpreted as to say that these papers have
found “a set”, (but not a unique “set”) of targets that are
therapeutically relevant. Finding a correct algorithm for
the combination of drugs that target a set of proteins
critical for sustaining cancer cells should be pursued.
In conclusion, recent results using new “omic” techni-
ques support the future use of targeted drug combina-
tions for the treatment of solid tumours. In our opinion
Normal stromal cell
Cancerized stromal cell
Cancer stem cell
Most abundant tumoral cells
Other tumoral cell subpopulations
Figure 2 Tumoral cell types that contribute to the heterogeneity of tumours. In addition to the most abundant tumoral cells, the genetic
instability of tumours is responsible for the establishment of genetically distinct tumoral cell subpopulations, which may escape genomic
detection as they may be diluted within the tumoral mass by the most abundant tumoral cells. Another important cellular component that
usually bears genomic and transcriptomic differences with respect to the majority of tumoral cells are the cancer initiating/stem cells. The
stromal cells that surround or are included into the tumoral mass may provide/receive proliferation/survival signals by crosstalking with tumoral
cells. In certain neoplastic diseases, the stromal cells critically contribute to the survival or dissemination of the tumoral cells, and may bear
genomic alterations that favour their tumor-supporting properties. These cancerized stromal cells and the rest of the cellular components of
tumours must be targetted to achieve an efficient antitumoral response.
Ocaña and Pandiella Molecular Cancer 2010, 9:202
http://www.molecular-cancer.com/content/9/1/202
Page 8 of 12to increase the efficiency of this process, it is critical to
reach a close collaboration between academia, the phar-
maceutical and biotechnological companies as well as
regulatory authorities to develop rationale studies with
drug combinations based on strong preclinical data.
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